VERTEX PHARMACEUTICALS INC / MA VRTX revenue by segment, product and geography
In its fiscal year ending 2025-12-31, VERTEX PHARMACEUTICALS INC / MA reported revenue across 1 business segments; the largest, Pharmaceuticals, was $12B, 100.0% of the filed sum (+8.9% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Pharmaceuticals$12B100.0%+8.9% yoy
Members sum to the consolidated $12B for this period.
- Product$12Bshare n/a+8.6% yoy
- TRIKAFTAKAFTRIO$10.3Bshare n/a+0.7% yoy
- ALYFTREK$838Mshare n/ano prior
- Manufactured Product Other$820Mshare n/a+4.9% yoy
- CASGEVY$116Mshare n/a+1058.0% yoy
- JOURNAVX$59.6Mshare n/ano prior
- Collaborativeand Royalty$30.7Mshare n/ano prior
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- United States$7.55Bshare n/a+12.9% yoy
- Outsidethe United States$4.45Bshare n/a+2.7% yoy
- Europe$3.46Bshare n/a+0.2% yoy
- Other Countries Outsideofthe United Statesand Europe$992Mshare n/a+12.6% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Pharmaceuticals$2.99B100.0%+7.8% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.